The timing appears opportune to go long in shares of The Chemours Company as we anticipate another pick-up in the underlying trend. Investors have an opportunity to buy the stock and target the $ 43.39.
The company has strong fundamentals. More than 70% of companies have a lower mix of growth, profitability, debt and visibility.
Overall, and from a short-term perspective, the company presents an interesting fundamental situation.
The equity is one of the most attractive in the market with regard to earnings multiple-based valuation.
The company has a low valuation given the cash flows generated by its activity.
Over the last twelve months, the sales forecast has been frequently revised upwards.
Sales forecast by analysts have been recently revised upwards.
For the past year, analysts covering the stock have been revising their EPS expectations upwards in a significant manner.
Analysts remain confident with respect to the group's activity and, more often than not, have revised upwards their earnings per share estimates.
There is high visibility into the group's activities for the coming years. Outlooks on future revenues from analysts covering the equity remain similar. Such hardly dispersed estimates support highly predictable sales for the current and upcoming fiscal years.
In relation to the value of its tangible assets, the company's valuation appears relatively high.
Disclaimer: The information, charts, data, views, or comments provided by SURPERFORMANCE SAS are intended for investors who have the necessary knowledge and experience to understand and appreciate the information contained within. These items are disseminated for personal reference only. They do not constitute an offer or solicitation to buy or sell financial products or services, nor an investment advice.
The use of the information disseminated takes place under the investor's sole responsibility, without recourse against SURPERFORMANCE SAS. SURPERFORMANCE SAS will not be liable, whether in contract, in tort, under any warranty, for errors, omissions, improper investments, or adverse evolution of markets.